°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¾à¸®Çб³½Ç
137-701 ¼­¿ïƯº°½Ã ¼­Ãʱ¸ ¹ÝÆ÷µ¿ 505¹øÁö ÀüÈ­: 02-590-1209(»ç¹«½Ç) FAX: 02-536-2485

1. ¾à »ç

º» ´ëÇп¡ ÀÇÇкΰ¡ 1954³â¿¡ Áõ¼³Àΰ¡¸¦ ¹Þ¾Æ ¹ßÁ·µÇ¾î 2³âÈÄÀÎ 56³â 3¿ù¿¡ ù ¾à¸®ÇÐ ±³¼ö·Î Á¶±ÔÂù ±³¼ö°¡ ºÎÀÓÇÏ¿© º» ´ëÇÐ ¾à¸®Çб³½Ç °³¼³¿¡ Èû¾²´Ù°¡ ±× ´ÙÀ½ ÇØÀÎ 57³â 3¿ù¿¡ »çÀÓÇÏ°í ³ëº´¸² Á¶±³¼ö°¡ ºÎÀÓÇÏ¿© ÀÇÇкΠÇлý¿¡ ´ëÇÑ ¾à¸®ÇÐ °­ÀÇ ¹× ½Ç½ÀÀ» ´ã´çÇÏ¿´´Ù. 58³â 5¿ù¿¡ À±±â³ç ±³¼ö°¡ º» ´ëÇп¡ ¾à¸®ÇÐ ±³¼ö·Î ºÎÀÓÇÏ¿´°í, 59³â¿¡´Â À̱³ÃæÀÌ, °ðÀ̾î Á¶º´ÇåÀÌ Á¶±³·Î ºÎÀÓÇÏ¿© ºñ·Î¼Ò ÀÎÀûÀÎ ¸é¿¡ ÀÖ¾î ±³½Ç·Î¼­ÀÇ ¸é¸ð¸¦ °®Ãß°Ô µÇ¾ú´Ù. 60³â 9¿ù ÃÊ´ë ¾à¸®ÇÐ ÁÖÀÓ±³¼ö¿¡ À±±â³ç ±³¼ö°¡ ÀÓ¸íµÇ¾úÀ¸³ª 61³â¿¡ º´È¯À¸·Î ÅðÁ÷ÇÏ°í ³ëº´¸² Á¶±³¼ö°¡ º» ±³½Ç ÁÖÀÓ±³¼ö ¼­¸®¸¦ ¸Ã°Ô µÇ¾ú´Ù. ÀÌ ´ç½Ã ¾à¸®Çб³½ÇÀº ¸íµ¿ÀÇ ±¸ ¼º¸ðº´¿ø ÀÚ¸®¿¡ ÀÖ´ø ±¸ ÁÖ±³ °Ç¹°¿¡ À§Ä¡ÇÏ°í ÀÖ¾úÀ¸¸ç ½ÇÇè±âÀç´Â º¸À߰;øÀÌ °Ü¿ì Çлý½Ç½À¿ë kymograph ¸î ´ë¿Í È­ÇÐõÆò ¹× ¿ÀºìÀÌ ÀüºÎ¿´´Ù. À̶§´Â ¿¬±¸¶õ ¾öµÎµµ ¸ø ³»°í Çлý°­ÀÇ¿¡¸¸ Àü³äÇß´Ù°í ÇÒ ¼ö ÀÖ¾ú´Ù. ±× ÈÄ 61³â Çö´ë½Ä °Ç¹°ÀÎ ¼º¸ðº´¿øÀÌ ½ÅÃàµÊ¿¡ µû¶ó ¾à¸®Çб³½ÇÀº ¼º¸ðº´¿øÀÇ ¸ÂÀºÆí¿¡ À§Ä¡ÇÑ ¼º´ç ±¸³»ÀÇ ±¸ °Ç¹°·Î ¿Å°ÜÁ³´Ù.

1963³â º» ´ëÇÐ 4ȸ Á¹¾÷»ýÀÎ ÀÌ»óº¹ÀÌ º»±³ Ãâ½Å ÃÖÃÊÀÇ Á¶±³·Î ÀÔ½ÇÇÏ¿´´Ù. ÀÌ ¶§ ºÎÅÍ Â÷Ãû Çмú¿¬±¸°¡ È°¹ßÇØÁ³´Âµ¥ ´ç½ÃÀÇ ³«ÈÄµÇ°í ºó¾àÇÑ ½Ã¼³ ¼Ó¿¡¼­´Â ÀÚ¿¬È÷ ¿¬±¸ ³»¿ëÀº ½ÇÇè½Ã¼³ÀÌ ´ú ÇÊ¿äÇÑ »ý¾à ¿¬±¸¿¡ ÁýÁߵǾú´Ù. ´ç½Ã ¿ì¸® ³ª¶ó ¾à¿ë½Ä¹°µé°ú ¹Î°£¿ä¹ýÀ¸·Î ³»·Á¿À´ø »ý¾à ÃßÃâ¹°¿¡ ´ëÇÑ ¾à¸®ÀÛ¿ëÀ» °ËÅäÇÏ¿´°í ¶ÇÇÑ È­ÇÐÀû ÇÕ¼º¹°À» ¸¸µé¾î À̵éÀÇ »õ·Î¿î ¾à¸®ÀÛ¿ëÀ» ±Ô¸íÇÏ·Á°í ³ë·ÂÇÏ¿´´Ù. ÇÑÆí erythropoietin¿¡ °üÇÑ ¿¬±¸¸¦ º´ÇàÇÏ¿´´Ù. ±×·¯´ø Áß¿¡ 1968³â¿¡ µé¾î ³ëº´¸² ±³¼ö´Â ¹Ì±¹ Å׳׽à ´ëÇÐ ¾à¸®Çб³½Ç·Î ¿¬±¸Â÷ ¶°³ª ±Í±¹ÇÏÁö ¾Ê°í 70³â¿¡ ±³¼öÁ÷À» »çÀÓÇÏ¿´´Ù. 68³â¿¡ º» ´ëÇÐÀÌ Á¾·Î±¸ °æ¿îµ¿ÀÇ ½ÅÃà±³»ç·Î ÀÌÀüÇÏ¿©, ¾à¸®Çб³½Çµµ Å« ¿¬±¸½ÇÀ» °®°Ô µÇ¾úÀ¸³ª ±³½Ç¿øµéÀÇ ±ºÀÔ´ë, µµ¹Ì´Â ¹°·Ð ½ÇÇè±âÀçÀÇ ºÎ½Ç µîÀ¸·Î Á¶º´Çå Á¶±³¼ö È¥ÀÚ¼­ °­ÀÇ¿Í ½Ç½ÀÀ» Àü´ãÇؾßÇÏ´Â ¾î·Á¿î ½ÇÁ¤À» ¸ÂÀÌÇÏ¿´´Ù.

1970³â¿¡ ¿¬¼¼ÀÇ´ë Á¶±Ôö ºÎ±³¼ö°¡ º»±³·Î ÀüÀÓÇÏ¿© º»±³½Ç ÁÖÀÓ±³¼ö¿¡ ÃëÀÓÇÏ¿´´Ù. ¹Ì³×¼ÒŸ ´ëÇп¡¼­ ÀÌÇйڻç ÇÐÀ§¸¦ ÃëµæÇÏ°í ¿ÀÇÏÀÌ¿À ´ëÇп¡¼­ ±³Æí»ýÈ°À» Çß´ø Á¶±Ôö ±³¼öÀÇ ºÎÀÓÀº º» ±³½ÇÀÌ Å©°Ô ¹ßÀüÇÏ´Â °è±â°¡ µÇ¾ú´Ù. À̶§ºÎÅÍ ±³½ÇÀÇ ¿¬±¸ºÐ¾ß´Â ÀÌ´¢Á¦¿Í ½ÉÇ÷°ü°èÀÇ µÎ ºÐ¾ß¿¡ ÁýÁߵǾú°í ¿¬±¸¿¡ ÇÊ¿äÇÑ ±âÀç°¡ ¼Ó¼Ó È®º¸µÇ¾î ¸í½Ç°øÈ÷ ¿¬±¸¿Í ±³À°À» º´ÇàÇÏ´Â ±³½Ç·Î¼­ÀÇ ¸é¸ð¸¦ °®Ãß°Ô µÇ¾ú´Ù. Á¶±Ôö ±³¼ö´Â 72³â 10¿ù¿¡ ´ëÇѾฮÇÐȸ ȸÀåÁ÷À» ¸Ã¾Æ 1³â°£ ÇÐȸ¸¦ À̲ø¾ú´Ù. 81³â¿¡´Â Á¶º´Çå ºÎ±³¼ö°¡ ±³¼ö·Î ½ÂÁøÇÏ°í µ¿³â 4¿ù ¼øõÇâ´ëÇÐÀÇ ÀÇÇкΠ¾à¸®Çб³½ÇÀÇ ÃÊ´ë ÁÖÀÓ±³¼ö·Î ¿µÀüÇÏ¿´´Ù.

1982³â 8¿ù¿¡ ÇöÀç À§Ä¡ÀÎ °­³²±¸ ¹ÝÆ÷µ¿À¸·Î ±³»ç°¡ ÀÌÀüµÊ¿¡ µû¶ó Çö´ë½Ä ½Ã¼³°ú ¸¹Àº ½ÇÇè±âÀ縦 È®º¸ÇÏ°Ô µÇ¾î ¿¬±¸ ¹× ±³À°ÀÇ ÁúÀ» ³ôÀÏ ¼ö ÀÖ´Â °è±â°¡ µÇ¾ú´Ù. 83³â µµ¹ÌÇÏ¿© ºê¶ó¿î ´ëÇÐ ¾à¸®Çб³½Ç¿¡¼­ ¹Ú»çÇÐÀ§ °úÁ¤À» ¸¶Ä£ ±èÀμøÀÌ 90³â Á¶±³¼ö·Î ÀÓ¸í¹Þ¾Æ ½Å»ýÇ÷°ü »ý¼º ±âÀü¿¡ °üÇÑ ¿¬±¸¸¦ ½ÃÀÛÇÏ¿´´Ù. 82³â ¼º±Õ°ü´ëÇÐ ¾à´ë¸¦ Á¹¾÷ÇÑ À̼®¿ë°ú 84³â¿¡ º»´ëÇÐ ÀÇÇаú¸¦ Á¹¾÷ÇÑ À̱ÇÇàÀÌ Á¶±³·Î ÀÔ½ÇÇÏ¿´´Ù. 83³â ÀÌ»óº¹ ºÎ±³¼ö´Â ±³¼ö·Î ½ÂÁøµÇ¾ú°í 87³â 10¿ùºÎÅÍ 1³â°£ ´ëÇѾฮÇÐȸ ȸÀåÀ» ¿ªÀÓÇÏ¿´À¸¸ç 91³â ÁÖÀÓ±³¼öÁ÷À» ¸Ã¾Æ ÇöÀç¿¡ À̸£°í ÀÖ´Ù. Á¶±Ôö ±³¼ö´Â 84³â 3¿ù¿¡ 3¡¤1¹®È­»ó(ÇмúºÎ¹®)À» ¼ö»óÇÏ¿´°í 86³âºÎÅÍ 4³â°£ ÀÇ°ú´ëÇÐÀåÀÇ Á÷Ã¥À» ¸Ã¾Æ Çб³ÀÇ ¹ßÀü¿¡ Å©°Ô À̹ÙÁöÇÏ¿´°í, 95³â Á¤³âÅðÁ÷ÇÏ¿© ¸í¿¹±³¼ö·Î Ãß´ëµÇ¾ú´Ù.

1985³â 3¿ù¿¡´Â º»±³ 26ȸ Á¹¾÷»ýÀÎ ±è¼ºÀ±ÀÌ, 88³â°ú 91³â¿¡ º»±³ ÀÇÇаú¸¦ Á¹¾÷ÇÑ ¼º±â¿í°ú Á¶¿µÁøÀÌ Á¶±³·Î ÀÓ½ÇÇÏ¿´´Ù. À̱ÇÇàÀº 92³âºÎÅÍ 94³â±îÁö ¹Ì±¹ NIH¿¡¼­ ¹Ú»çÈÄ °úÁ¤À» ¸¶Ä¡°í ±Í±¹ ÇöÀç phospholipase C µ¿À§È¿¼Ò¿¡ ´ëÇÑ ¿¬±¸¸¦ ÇÏ°í ÀÖÀ¸¸ç, À̼®¿ëÀº 93³âºÎÅÍ 95³â±îÁö ¹Ì±¹ ¹Ì³×¼ÒŸ ´ëÇп¡¼­ ¹Ú»çÈÄ ¿¬¼ö¸¦ ¸¶Ä£ ÈÄ ÇöÀç nitric oxide¿¡ °üÇÑ ¿¬±¸¸¦ ÇÏ°í ÀÖ´Ù. ±è¼ºÀ±Àº 95³âºÎÅÍ ÇöÀç±îÁö ¹Ì±¹ ·Î¿ç¶ó´ëÇп¡¼­ ¹Ú»çÈÄ °úÁ¤ ÁßÀÌ´Ù. ÀÌ»óº¹ ±³¼ö´Â 94³âºÎÅÍ ÇöÀç±îÁö º» ÀÇ°ú´ëÇÐ ÇÐÀåÀ» ¿ªÀÓÇϸ鼭 ÀÇ°ú´ëÇÐÀÇ ¹ßÀü¿¡ Å« ±â¿©¸¦ ÇÏ¿´À¸¸ç 96³â¸» °³¿øµÈ °¡Å縯´ëÇÐ ÀÇ°úÇÐ ¿¬±¸¿ø »êÇÏ ½Å¾à°³¹ß¿¬±¸¼ÒÀåÀ» ¸Ã¾Æ ±âÃÊ¿Í ÀÓ»ó°£ÀÇ ¿¬±¸±³·ù¿¡ À̹ÙÁöÇÏ°í ÀÖÀ¸¸ç ¾Æ¿ï·¯ 96³âºÎÅÍ Çѱ¹½Å°æ°úÇÐȸ ȸÀåÁ÷À» ¸Ã¾Æ ÇöÀç±îÁö ÇÐȸ¸¦ ÁÖ°üÇÏ°í ÀÖ´Ù.

 
2. ¿ª´ë ±³½Ç¿ø ¸í´Ü
1) ÇöÁ÷±³½Ç¿ø
¼º   ¸í
ÀçÀӱⰣ
ÃÖÁ¾Á÷±Þ
ŸÇÐȸȰµ¿
ÀÌ»óº¹

63.3-

±³      ¼ö

½Å°æ°úÇÐȸ ȸÀå

±è¿Á³à
70.5-
±³      ¼ö
À̱ÇÇà
84.5-
ºÎ ±³ ¼ö
À̼®¿ë
82.9-
ºÎ ±³ ¼ö
±è¼ºÀ±
85.3-
Á¶ ±³ ¼ö
¼º±â¿í
88.3-
Á¶ ±³ ¼ö
Á¶¿µÁø
91.3-
ÀüÀÓ°­»ç
±è¼±Çü
95.3-
Á¶      ±³
ÃÖÁö¿õ
96.3-
Á¶      ±³
°­Á¤Çý
96.3-
Á¶      ±³
ÀÌ¿î±Ô
96.9-
Á¶      ±³
±èÀºÁ¤
97.2-
Á¶      ±³
ÃÖÁøÈñ
97.2-
Á¶      ±³

2) ÀüÁ÷±³½Ç¿ø
¼º   ¸í
ÀçÀӱⰣ
ÃÖÁ¾Á÷±Þ
ŸÇÐȸȰµ¿
Á¶±ÔÂù

56.3-57.3

±³      ¼ö

 

³ëº´¸²
57.6-70.4
±³      ¼ö
À±±â¿µ
58.5-61.7
±³      ¼ö
Á¶±Ôö
70.5-95.8
±³      ¼ö
¸í¿¹±³¼ö
Á¶º´Çå
59.11-81.3
±³      ¼ö
¼øõÇâÀÇ´ë±³¼ö
±èÀμø
78.3-93.3
Á¶ ±³ ¼ö
ÀÌ´öÈñ
64.3-76.2
ÀüÀÓ°­»ç
Àç¹Ì
¹ÚöÈÆ
70.3-76.5
ÀüÀÓ°­»ç
ÀÌÈ«¹ü
70.3-76.5
ÀüÀÓ°­»ç
À̱³Ãæ
59.4-63.3
Á¶      ±³
ÃÖ¿ì½Ä
61.4-63.2
Á¶      ±³
±èÈñ¼ø
68.3-69.9
Á¶      ±³
°í±¤È£
69.12-71.5
Á¶      ±³
¼­¿ï¾à´ë ±³¼ö
À嵿¿ø
71.9-76.9
Á¶      ±³
ÀÌÁ¾È­
72.3-76.3
Á¶      ±³
»ïÀ°´ë ±³¼ö
½ÉÁß¿±
74.3-74.8
Á¶      ±³
Á¤Àμ÷
76.3-78.2
Á¶      ±³
ÀÌÁ¾Çå
76.3-77.11
Á¶      ±³
¿°À±Èñ
78.3-82.2
Á¶      ±³
ÀÌ°è½Ç
80.3-80.3
Á¶      ±³
¾çÀçÇÏ
81.3-82.2
Á¶      ±³
´ë±¸ÇÑÀÇ´ë ±³¼ö
ÀÌ¿µ¼÷
82.3-83.2
Á¶      ±³
¹æ¾Ö°æ
82.9-85.8
Á¶      ±³
¼­¿µÁø
83.3-89.12
Á¶      ±³
Á¶È«µ¿
89.3-92.2
Á¶      ±³
±èÁ¤Èñ
90.3-94.2
Á¶      ±³
±èÁ¤Áø
92.3-95.2
Á¶      ±³
ÀÓÇý¼÷
94.3-96.2
Á¶      ±³
¹Ú»ó¿ø
95.3-96.2
Á¶      ±³
ÀÓ¼ö°æ
95.3-96.2
Á¶      ±³
ÁÖ¿ìÁ¤
96.3-96.9
Á¶      ±³
ÀüÁß¿µ
96.3-97.2
Á¶      ±³

 

3. ¿¬±¸ È°µ¿

1) ¿ª´ë ±³½Ç¿øµéÀÇ Áֿ俬±¸ºÐ¾ß
±³½Ç¿ø
Áֿ俬±¸ºÐ¾ß
±³½Ç¿ø
Áֿ俬±¸ºÐ¾ß
Á¶±ÔÂù
±è¿Á³à
¿Ü»ó¾à¸®
¾îº´ÀÓ
±èÀμø
ºÐÀھฮ
À±±â¿µ
À̼®¿ë
½Å°æ¾à¸®
Á¶±Ôö
½ÅÀå¾à¸®
À̱ÇÇà
ºÐÀھฮ
ÀÌ»óº¹
ÁßÃ߽Űæ¾à¸®, ÀÓ»ó¾à¸®

2) ±³½Ç¿ø ÇØ¿Ü¿¬¼ö
¼º      ¸í
±â      °£
±â      °ü
³ëº´¸²
68.3-
¹Ì±¹ Å׳׽ôëÇÐ ¾à¸®Çб³½Ç
Á¶º´Çå
77.8-78
ÀϺ» µµ¾ß¸¶ÀÇ´ë È­Çבּ¸¼Ò
ÀÌ»óº¹
75.5-
Æĸ®ÀÇ°ú´ëÇÐ ¾à¸®Çб³½Ç
±è¿Á³à
87-89
¹Ì±¹ ¸Þ¸±·£µå´ëÇб³ ¾àÇдëÇÐ
±èÀμø
83.9-90.3
¹Ì±¹ºê¶ó¿î´ëÇÐ ¾à¸®Çб³½Ç
À̱ÇÇà
92.6-94.7
¹Ì±¹ NIH
À̼®¿ë
93.8-95.9
¹Ì±¹ ¹Ì³»¼ÒŸ´ëÇÐ ¾à¸®Çб³½Ç
±è¼ºÀ±
95.3-
¹Ì±¹ ·Î¿ç¶ó´ëÇÐ ¾à¸®Çб³½Ç

3) ¿¬µµº° ³í¹® ¹ßÇ¥ ÇöȲ

<1961¡­1965>
<±¹ ³»>

ÀÌ»óº¹: À°¾ÆÁ¾³¶¹ý(Granuloma pouch technic)À» ÀÌ¿ëÇÑ Steroid È­ÇÕ¹°ÀÇ ¼Ò¿°ÀÛ¿ë ºñ±³. ´ëÇѾฮÇÐȸÀâÁö 1(1): 47-51, 1965.
½ÅÇöö, ³ëºÀÅÃ: ÀûÃâ °³±¸¸® ½ÉÀå¿¡ ´ëÇÑ BradydininÀÇ ÀÛ¿ë. Kor Med J 10(3): 63-66, 1965. .

<1966¡­1970>
<±¹ ³»>

¼­°æ¿Á: ´«ºû½Â¸¶ ¾ËÄÝÀ¯Ãâ¹°ÀÇ ÀûÃâÁ¶°³ ½ÉÀå¹Úµ¿¿¡ ´ëÇÑ ÀÛ¿ë. Kor Med J 12(7): 45-50, 1967.
À̱Կë: ¸ÅÀÚ³ª¹«±Ù °áÁ¤(A)ÀÇ ÀûÃâÁ¶°³ ½ÉÀå¹Úµ¿ ¹× °³±¸¸®º¹Á÷±Ù¿¡ ´ëÇÑ ÀÛ¿ë. Kor Med J 13(3): 19-25, 1968.
Á¶¿ëÀÏ, À̱Կë: ¼öÁ¾¾à¹°ÀÌ °³±¸¸®ÀÇ ÀûÇ÷±¸¿¡ ´ëÇÑ ¿µÇâ. Kor Med J 13(3): 27-30, 1968.
À̱Կë, Á¶¿ëÀÏ: ȸ¾ç¸ñ ¾ËÄÝÃßÃâ¹°ÀÇ ¹é¼­ÀûÃâÀ۱ÿ¿¡ ´ëÇÑ ÀÛ¿ë. Kor Med J 13(3): 31-34, 1968.
¹ÚÁ¤¼ø, ±èÀ±±Ù: ¿ì¸®³ª¶ó ¹éºÎÀÚ(Aconitum Koreanum R. Raymond)ÀÇ ÀûÃâ °³±¸¸® ½ÉÀå ¿îµ¿¿¡ ´ëÇÑ ÀÛ¿ë ¹× LD50. Kor J Pharmacol 5(2): 1-5, 1969.
¹ÝµÎ°æ, ½Éö, ÀÓ¿ëÈ£: ÀͺÎÃÊ Alcohol ÃßÃâ¹°ÀÇ ÀûÃâ°¡Åä Àå¿îµ¿¿¡ ´ëÇÑ ÀÛ¿ë. Kor Med J 14(1): 37-40, 1969.
ÀüÈñ¼ø, ±èÀ±±Ù, ±è¿Á³à: À¸¾Æ¸®±ÙÀÇ ¾ËÄÝÃßÃâ¹°ÀÇ °³±¸¸® º¹Á÷±Ù¿¡ ´ëÇÑ ÀÛ¿ë. Kor Med J 14(1): 31-36, 1969.
¼Û¼®±Ô: ³ì¿ëÀÌ Åä³¢ÀÇ Á¶Ç÷ÀÎÀÚ ¹× ¹æ»ç¼ºÃ¶ ¼·Ãë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý. 18: 51-60, 1970.
¹ÚÁ¤¼ø: °í·ÁÀλïÀÇ °¢ ºÐ·ù¹°ÀÌ Åä³¢ÀÇ Á¶Ç÷ÀÎÀÚ¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý. 19: 55-68, 1970.
±è¿Á³à: À¸¾Æ¸® »Ñ¸®ÀÇ ¾ËÄÝÃßÃâ¹°ÀÌ ÀûÃâ °¡ÅäÀå°ü¿îµ¿¿¡ ¹ÌÄ¡´Â¿µÇâ. Áß¾ÓÀÇÇÐ 19(4): 293-298, 1970.

<1971¡­1975>
<±¹ ³»>

ÀÌ»óº¹, ÀÌ´öÈñ, ÀÌÈï¹ü: ÀλïÀÌ Á¶Ç÷ ±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. ÃÖ½ÌÀÇÇÐ. 14(3): 91-95, 1971.
ÀÌ»óº¹, Á¶±Ôö: ÀλïÀÌ ½ÇÇèÀû ÄáÆϼº °íÇ÷¾Ð¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý. 20: 89-99, 1971.
ÀÌ»óº¹, ¹ÚÇü°æ: ¹é¼­ Ç÷ÀåÁ¶Ç÷ÀÎÀÚ È°¼º¿¡ ¹ÌÄ¡´Â hypoxiaÀÇ ¿µÇâ. ÃÖ½ÅÀÇÇÐ 14(2): 91-93, 1971.
È«À±Ç¥: °¡ÅäÀÇ ¿ä»ê¹è¼³¿¡ °üÇÑ ½ÇÇèÀû ¿¬±¸. ´ëÇѾฮÇÐȸÁö. 7: 67-74, 1971.
ÀÌ´öÈñ, ¹ÚöÈÆ, ÀÌ»óº¹: ÀλïÀÌ ÀûÇ÷±¸ ö¼·Ãë¿¡ ¹ÌÄ¡´Â ¿µÇâ. Áß¾ÓÀÇÇÐ 20(2): 167-170, 1971.
ÀÌ»óº¹, ÀÌ´öÈñ, ÀÌÈï¹ý: ÀλïÀÌ Á¶Ç÷±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. ÃÖ½ÅÀÇÇÐ 14(3): 91-95, 1971.
ÇϺ´±¹, ±èÀ¯¼º, ±è¿øÀÚ, ¹ÚöÈÆ: ¿ì¸®³ª¶ó ¹éºÎÀÚÀÇ ÀûÃâ Á¶°³ ½ÉÀå¿îµ¿¿¡ ´ëÇÑ ÀÛ¿ë. ´ëÇѾฮÇÐÀâÁö 8(1): 15-25, 1972.
À¯¸í¿­, ¹ÚÇü°æ, ÀÌÁ¤ÀÍ: ¸¶¿ì½º Carbonic anhydrase È°¼º¿¡ ¹ÌÄ¡´Â Xanthine À¯µµÃ¼ÀÇ ¿µÇâ. ´ëÇѾฮÇÐÀâÁö 8(1): 59-62, 1972.
ÀÌ´öÈñ, ±è±âÁø, ¹ÚÇü°æ: BradykininÀÌ Guanethidine Àüóġ °¡ÅäÀÇ Ç÷¾Ð¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐÀâÁö 8(1): 63-65, 1972.
Á¶±Ôö: Ç׾Ϲ°Áú°ú ±× À¯ÇØÀÛ¿ë. ´ëÇÑÀÇÇÐÇùȸÁö 15(9): 23-28, 1972.
¹ÚÇü°æ: ¼öÀºÀÌ´¢Á¦ÀÇ »ýü³» ºÐÆ÷. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 22: 131-138, 1972.
ÀÌÁ¤ÀÍ: °¨³ª¹« ¼ººÐÀÇ °áÁ¤È­ ¹× ÈòÁãÇ÷¾Ð¿¡ ´ëÇÑ ÀÛ¿ë. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 22: 139-146, 1972.
ÀÌ´öÈñ, Á¶±Ôö: AcetazolamideÀÇ Carbonic AnhydraseÈ°¼º ¾ïÁ¦ÀÛ¿ë¿¡ ´ëÇÑ Xanthine À¯µµÃ¼ÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 23: 15-24, 1972.
±è±âÁø: žÆÀÇ ÀûÇ÷±¸ »ý¼º Á¶Àý±â´É. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 23: 49-57, 1972.
Á¶±Ôö: ¾à¹°»óÈ£ÀÛ¿ë. ´ëÇѾฮÇÐÀâÁö 8(2): 5-20, 1972.
¹ÚöÈÆ, ÇϺ´±¹, ¹é¿î»ó, ÇѽÃÁØ: ¿Á¼ö¼ö ¼ö¿°ÀÇ ¹° ÃßÃâ¹°ÀÌ Ç÷¾Ð¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÁö 8(2): 1-6, 1972.
±è¿Á³à: ´ëȲ¼ººÐ°ú ±×¿Ü ¾à¹°µéÀÇ ÈòÁã À§±Ë¾ç ¹æ¾îÀÛ¿ë. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 23: 37-45, 1972.
ÀÌ´öÈñ, À嵿¿ø, ÀÌ»óº¹: P-dimethylaminobenzaldehyde ÀÇ Ç×Áø±ÕÀÛ¿ë. Áß¾ÓÀÇÇÐ 22: 27, 1972.
Á¶º´Çå, ÀÌ»óº¹, ÀÌ´öÈñ, ¹ÚöÈÆ: ÀλïÀÌ ½ÇÇèÀû °íÇ÷¾Ð¿¡ ¹ÌÄ¡´Â ¿µÇâ ¹× ±× ±âÀü¿¡ °üÇÑ ¿¬±¸. ´ëÇѾฮÇÐȸÀâÁö 8(1): 49-57, 1972.
±è¿øÀÚ, ¹é¿î»ó, ÇÏ¸í±¹, ±è±âÁø: ´ëȲÀÇ ¾ËÄÝ ÃßÃâ¹°ÀÌ Åä³¢ ÀûÃâÀå°ü¾Ö ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÁö. 8(1): 77-87, 1972.
±è¿Á³à, ÀÌÁ¤ÀÍ, ¹ÚÀºÈ£: ´ëȲÀÇ ¾ËÄÝÃßÃâ¹°ÀÌ ÈòÁã Àå°ü ¹× À§¿îµ¿¿¡ ¹ÌÄ¡´Â ¿µÇâ. Áß¾ÓÀÇÇÐ 22(2): 153-157, 1972.
¹ÚÀºÈ£: AcetozolamideÀÇ ¾È¾Ð °­ÇÏÀÛ¿ë¿¡ ´ëÇÑ XanthineÀ¯µµÃ¼ÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 23: 175-183, 1972.
¹é¿î»ó: Corticosyteroids Á¡¾ÈÀÌ ¾È¾Ð ¹× Acetazolamide ÀÇ ¾È¾ÐÇÏ°­ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 24: 11-18, 1973.
À¯¸í¿­: GlucocorteroidÀÇ ÀûÇ÷±¸ »ý¼º±â´É¿¡ ´ëÇÑ ÀÛ¿ë. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 24: 151-159, 1973.
ÇѽÃÁØ: ¿Á¼ö¼ö ¼ö¿° ¼ººÐÀÇ ¾à¸®Àû ÀÛ¿ë. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 25: 293-304, 1973.
ÀÌÁ¾È­, Á¶¼±Èñ, ¼Ûº´¼÷, ¹é¿î»ó: Á¦Ã汹ȭ À¯Ãâ¹°ÀÇ Ç×Áø±ÕÀÛ¿ë. ´ëÇѾฮÇÐÀâÁö 9(1): 17-22, 1973.
±è¿øÀÚ, Á¶¼±Èñ, ¼Ûº´¼÷, ÇϺ´±¹: ¿Á¼ö¼ö ¼ö¿°ÀÇ ¹° ÃßÃâ¹°ÀÌ Åä³¢ ÀûÃâ Àڱÿ¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐÀâÁö 9(1): 1-9, 1973.
ÀÌÁ¾È­, ±è¿øÀÚ, ¼Ûº´¼÷, Á¶¼±Èñ: ¹é¿©·Î±Ù°æ ÃßÃâ¹°ÀÇ Ç×Áø±ÕÀÛ¿ë. ´ëÇѾฮÇÐÀâÁö 9(2): 21-27, 1973.
¹ÚöÈÆ, ±èÁ¤ÀÏ: ¾çä¼ÛÈ­ÀÇ ¾ËÄÚȦ ÃßÃâ¹°ÀÌ ÀûÃâ Á¶°³ ½ÉÀå ¿îµ¿¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐÀâÁö 9(2): 29-37, 1973.
±èÀ¯¼º, Á¶±Ôö: AcetazolamideÀÇ Carbonic AnhydraseÈ°¼º ¾ïÁ¦ÀÛ¿ë¿¡ ´ëÇÑ CorticosteroidsÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 24: 69-78, 1973.
ÇϺ´±¹, Á¶±Ôö: AcetazolamideÀÇ Carbonic AnhydraseÈ°¼º ¾ïÁ¦ÀÛ¿ë¿¡ ´ëÇÑ DOCA ¹× Fludrocortisone ÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 24: 237-247, 1973.
±è¿øÀÚ, Á¶±Ôö: AcetazolamideÀÇ Carbonic AnhydraseÈ°¼º ¾ïÁ¦ ÀÛ¿ë¿¡ ´ëÇÑ Progesterone ¹× Estradiol ÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 25: 115-125, 1973.
ÀÌÁ¾È­, ¼Ûº´¼÷, Á¶¼±Èñ, ±èÁ¤ÀÏ: Å亹·É ¾ËÄÚ¿Ã ÃßÃâ¹°ÀÇ ÇÑÁø±ÕÀÛ¿ë. ´ëÇѾฮÇÐȸÁö 9(2): 39-45, 1973.
ÀÌÁ¾È­, ±èÁ¤ÀÏ, ¼Û¹ÎÀÚ: Å亹·É ¾ËÄÚ¿Ã ÃßÃâ¹°ÀÌ Åä³¢ÀûÃâ ½ÊÀÌÀå°ü¿îµ¿¿¡ ¹ÌÄ¡´Â¿µÇâ. ´ëÇѾฮÇÐȸÁö 9(2), 47-53, 1973.
¾î¿µ¼±: ¾çÃø ´¢°ü °áÂû°ú ¾çÃø ½ÅÀûÃâÀÌ Erythropoietin È°¼º¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 24: 371-384, 1973.
¹Ú°æ¼÷: Åä³¢ Àڱÿ¿¡ ¹ÌÄ¡´Â Ȳ·Ã¼ººÐÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 24, 57-68, 1973.
Á¶º´Çå, ÀÌ»óº¹, ¹ÚöÈÆ: ¼±ÀÎÀå(Opuntia elata) ¿¡Åº¿Ã ÃßÃ⼺ºÐÀÇ ¾à¸®ÀÛ¿ë. ´ëÇѾฮÇÐȸÁö 10(2): 43-54, 1974.
¼Ûº´¼÷, Á¶±Ôö: AcetazolamideÀÇ Carbonic AnhydraseÈ°¼º ¾ïÁ¦ ÀÛ¿ë¿¡ ´ëÇÑ Hydrocortisone °ú Aminophylline º´ÇÕÅõ¿©ÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 26: 363-372, 1974.
ÃÖ¸íÇÐ: Estradiol ¹× ProgesteroneÀÌ Á¶Ç÷±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 26: 385-392, 1974.
Á¶±Ôö: Enzyme Therapy. ´ëÇÑ»ýÈ­ÇÐÇùȸÁö 6(2): 59-62, 1974.99
Á¶±Ôö, ÀÌ»óº¹, ÀÌ´öÈñ, ÀÌÁ¾È­: ºÎ½ÅÇÇÁú È£¸£¸óÀÌ Ç÷Àå Erythropoietin È°¼º¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÀâÁö 10(2): 55-62, 1974.
ÀÌÁ¾È­, ÀÌ´öÈñ, Á¶±Ôö: HydrocortisoneÀÇ ½Åµ¿¸Æ ÁÖÀÔÀÌ acetazolamide ¹× aminophyllineÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÁö 10(2): 63-74, 1974.
¼Û¹ÎÀÚ: ÅûçÀÇ ÀÌ´¢ÀÛ¿ë. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 27: 177-186, 1974.
¹ÚöÈÆ: ¼±ÀÎÀå ¾ËÄÚ¿Ã ÃßÃâ ¼ººÐÀÇ ¾à¸®ÀÛ¿ë. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 27: 667-673, 1974.
±èÁ¤ÀÏ: Åä³¢ Àڱÿ¿¡ ¹ÌÄ¡´Â »çöä¼ÛÈ­ ¼ººÐÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 26: 123-134, 1974.
Á¶¼±Èñ, ±èÁ¤ÀÏ: ¸ÅÀÚ³ª¹«¼ººÐÀÌ ¸¶¿ì½º ¼ö¸é ¹× ü¿Â¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÁö 10(1): 61-65, 1974.
±è¿Á³à: Ȳ·Ã¼ººÐÀÇ ÀûÃâÁ¶°³ ½ÉÀå¿îµ¿¿¡ ´ëÇÑ¿¬±¸. Áß¾ÓÀÇÇÐ 33(3): 303-307, 1974,.
À嵿¿ø, ÀÌ»óº¹, Á¶±Ôö: AcetazolamideÀÇ Carbonic Anhydrase È°¼º¾ïÁ¦ ÀÛ¿ë¿¡ ´ëÇÑ TestosteroneÀÇ ¿µÇâ. ´ëÇѾฮÇÐȸÀâÁö 11(2): 1-8, 1975.

<1976¡­1980>
<±¹ ³»>

°ûÀμ÷, ÀÌ»óº¹, Á¶º´Çå, Á¶±Ôö: Ȳ·Ã¼ººÐÀÇ Ç÷¾ÐÇÏ°­ÀÛ¿ë. ´ëÇѾฮÇÐȸÀâÁö 12(2): 61-64, 1976.
ÀÌÁ¾È­, Á¶±Ôö: °¡ÅäÀÇ ½Åµ¿¸Æ¿¡ ÁÖÀÔÇÑ Norepinephrine, Epinephrine ¹× AcetylcholineÀÌ ½ÅÀå±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 29: 55-67, 1976.
ÀÌÁ¾È­, Á¶º´Çå: µî½ÉÃÊ°¡ Åä³¢ ½ÅÀå±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. ÃÖ½ÅÀÇÇÐ 19(4): 435-443, 1976.
À嵿¿ø, ¹ÚöÈÆ, Á¶º´Çå, Á¶±Ôö: ¼öÁ¾»ý¾àÀÇ ÀÌ´¢È¿°ú °üÂû¼Ò°ß. Áß¾ÓÀÇÇÐ 30(2): 191-197, 1976.
Á¶±Ôö: ¼öÀºÀÌ´¢Á¦. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 30(1): 1-15, 1976.
ÀÌÁ¾Çå, ÀÌ»óº¹, Á¶º´Çå, Á¶±Ôö: AcetazolamideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â HydrocortisoneÀÇ Áõ°­ÀÛ¿ë. Áß¾ÓÀÇÇÐ 32(1): 11-16, 1976.
ÀÌ»óº¹, Á¶±Ôö: ClonidineÀÇ ÁßÃß¼º ±³°¨½Å°æ¾ïÁ¦ÀÛ¿ë¿¡ ´ëÇÑ dopamine Â÷´ÜÁ¦ÀÇ ¿µÇâ. ´ëÇÑÀÇÇÐÇùȸÁö 20(2): 1-7, 1977.
±è¿Á³à: Ȳ·Ã¼ººÐÀÇ ÀûÃâÁ¶°³ ½ÉÀå¿îµ¿¿¡ ´ëÇÑ¿¬±¸. Áß¾ÓÀÇÇÐ 33(3): 303-307, 1977.
ÀÌ»óº¹, ±è¿Á³à, Á¶º´Çå, Á¶±Ôö: Çѱ¹»ê »ý¾àÁ¦µéÀÇ Ç÷¾ÐÇÏ°­ÀÛ¿ë¿¡ ´ëÇÑ ¿¬±¸: I. Ȳ·Ã, Åûç, ¿À°¡ÇÇ. ÃÖ½ÅÀÇÇÐ 21(4): 71-79, 1977.
ÀÌÁ¾Çå, Á¶±Ôö: AcetazolamideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â HydrocortisoneÀÇ Áõ°­ÀÛ¿ë ºÎÀ§. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 31(1): 189-193, 1978.
°ûÀμ÷, Á¶±Ôö: HydrocortisoneÀÌ AcetazolamideÀÇ Carbonic Anhydrase È°¼º¾ïÁ¦ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 31(1): 195-199, 1978.
±è¿Á³à, ÀÌ»óº¹: µÎÃæ ¸ÞŸ³îÃßÃâ¹°ÀÇ Ç÷¾ÐÇÏ°­ ÀÛ¿ë. ÃÖ½ÅÀÇÇÐ 21(3): 1-5, 1978.
Á¶±Ôö: Endogenous opioid peptides¿¡ ´ëÇÏ¿©. ÃÖ½ÅÀÇÇÐ 21(7). 20-23, 1978.
Á¶º´Çå, ±èÀÎÈ£, ÀÌ»óº¹, Á¶±Ôö, ÀÌÁ¾È­: Çѱ¹»ê »ý¾àÁ¦µéÀÇ Ç÷¾Ð°­ÇÏÀÛ¿ë¿¡ ´ëÇÑ ¿¬±¸ (II). ´ëÇѾฮÇÐȸÀâÁö 15(1): 45-56, 1979.
ÀÌ»óº¹, ¿°À±Èñ, ÀÌÁ¾È­, ±è¿Á³à, Á¶±Ôö: ¹«¸¶Ãë Åä³¢ÀÇ Ãø³ú½Ç·Î Åõ¿©µÈ PropranololÀÇ Ç÷¾Ð°­ÇÏ ÀÛ¿ë. Àΰ£°úÇÐ 3(4): 45-51, 1979.
ÀÌÁ¾È­, ÀÌ»óº¹, Á¶º´Çå, Á¶±Ôö: ¥á-Tri-thio-acetaldehydeÀÇ ¾à¸®ÀÛ¿ë (1): Ç÷¾Ð°­ÇÏÀÛ¿ë ¹× ÀÌ´¢ÀÛ¿ë. Áß¾ÓÀÇÇÐ 36(1): 65-73, 1979.
ÀÌÁ¾È­, ±èÀμø, ±è¿Á³à, Á¶º´Çå, Á¶±Ôö: Çѱ¹»ê »ý¾àÁ¦µéÀÇ Ç÷¾Ð°­ÇÏÀÛ¿ë¿¡ ´ëÇÑ ¿¬±¸(¥²):¹Ú´Þ¼öÇÇÀÇ Ç÷¾å¿¡ ´ëÇÑÀÛ¿ë. Çѱ¹»ý¾àÇÐȸÁö 10(3): 125-135, 1979.
±èÀμø, Á¶±Ôö: Reserpine Àüóġ°¡ Furosemide ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 32(1): 27-36, 1979.
±èÀμø, ÀÌ»óº¹, Á¶±Ôö: Penicillin G ÁÖÀÔÀÌ Furosemide ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÀâÁö 16(2): 9-14, 1980.
È«°üÈñ, Á¶±Ôö: Hydrocortisone Àüóġ°¡ Furosemide ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 33(3): 471-476, 1980.
±è¼ºÀÚ, Á¶±Ôö: ¾ËÄ«¸®¼º ´¢°¡ Furosemide ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 33(3): 477-481, 1980.
ÀÌÁ¾È­, Á¶±Ôö: Åä³¢ ½ÅÀå¿¡¼­ PAHÀÇ ÀÌ´¢ÀÛ¿ë°ú À¯±â»êÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 33(4): 759-772, 1980.
±èÀμø, ¿°À±Èñ, ÀÌ»óº¹, Á¶º´Çå, Á¶±Ôö: ¼öÁ¾»ý¾àÁ¦°¡ ½Å±â´É ¹× ½ÅÀå Na+-K+-ATPase¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÀâÁö 16(1): 51-56, 1980.

<1981¡­1985>
<±¹ ³»>

Yeom YH, Lee JH, Kim IS, Kim ON, Cho KC: Effect of acetazolamide on the diuretic action of furosemide in rabbits. Kor J Pharmacol 17(2): 63-67, 1981.
¿°À±Èñ, ¿ëÀçÀÍ, Á¶±Ôö: FurosemideÀÇ °¡Åä ½Å¼¼´¢°ü ¼ö¼Û¿¡ ´ëÇÑ CephalexinÀÇ ¿µÇâ. Àΰ£°úÇÐ 5(3): 49-55, 1981.
ÀÌ¿µÈñ, Á¶±Ôö: Prostaglandin E1ÀÌ ÈòÁã ½ÅÁ¶Á÷³» Carbonic Anhydrase È°¼º¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 34(3): 405-410, 1981.
±è±¤¼ö: FurosemideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ´ëÇÑ Acetazolamide ¹× MersalylÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 34(4): 655-668, 1981.
±èÀÎÈ£, ÀÌ»óº¹: Äݸ°¼º ¾à¹°ÀÇ ÁßÃßÅõ¿©°¡ ½ÉÇ÷°ü°è¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 34(4): 669-679, 1981.
±èÀμø, ¿°À±Èñ, ÀÌ»óº¹, Á¶º´Çå, Á¶±Ôö: ClonidineÀÌ °¡Åä ½Å±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. Àΰ£°úÇÐ 5(4): 65-67, 1981.
ÀÌ»óº¹, ±èÀμø, ±è¿Á³à, Á¶±Ôö: ½ÉÇ÷°ü°èÀÇ ÁßÃßÁ¶Àý¿¡ ´ëÇÑ Prostaglandin F2¥áÀÇ ¿µÇâ. ´ëÇѾฮÇÐȸÀâÁö 18(1): 11-16, 1982.
Á¶±Ôö, ±èÀμø, ¾çÀçÇÏ, ¹Ú¿µ¼­: ÈòÁã ½ÅÁ¶Á÷³» Cyclic Nucleotide ÇÔ·®¿¡ ¹ÌÄ¡´Â Hydrocortisone °ú FurosemideÀÇ ¿µÇâ. Kor J Pharmacol 19(1): 93-99, 1983.
¹Ú¿µ¼­: FurosemideÀÇ ÀÌ´¢ÀÛ¿ë°ú ½ÅÁ¶Á÷³» cyclic nucleotide ÇÔ·®¿¡ ¹ÌÄ¡´Â hydrocortisoneÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 36(2): 515-525, 1983.
À̿쿵, Á¶±Ôö: ÈòÁãÀÇ ½ÅÁ¶Á÷³» cyclic nucleotides¿¡ ¹ÌÄ¡´Â ÀÌ´¢Á¦ÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 36(1): 23-28, 1983.
ÀÌÃæÈÆ, Á¶±Ôö: ÈòÁã ½ÅÁ¶Á÷³» carbonic anhydrase¿¡ ¹ÌÄ¡´Â furosemide¿Í prostaglandin E1ÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 36(1): 29-35, 1983.
±èÀμø, ÀÌ»óº¹, Á¶±Ôö: Vanadium ÀÌ ½ÅÀå Na-K-ATPase ¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѾฮÇÐȸÀâÁö 19(1): 449-454, 1983.
ÀÌ»óº¹: ½ÉÇ÷°ü°èÀÇ ÁßÃßÁ¶Àý¿¡ ´ëÇÑ DopamineÀÇ ¿µÇâ. Áß¾ÓÀÇÇÐ 44(2): 153-157, 1983.
Á¤À±¸ð: FurosemideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ´ëÇÑ ¼Ò¿°Á¦ÀÇ ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 36(2): 383-393, 1983.
¹Ú¿ì¹è: ¹«¸¶Ãë ÈòÁãÀÇ Ãø³ú½ÇÀÇ Åõ¿©ÇÑ Prostaglandin E2, F2aÀÇ ½ÉÇ÷°ü°è¿¡ ´ëÇÑ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 36(2): 395-403, 1983
À̱ÇÇà, Á¶±Ôö: Vanadate°¡ Åä³¢ ½ÊÀÌÁöÀåÀÇ ¼öÃà·Â¿¡ ¹ÌÄ¡´Â È¿°ú. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 37(1): 7-12, 1984.
½ÅÀͱÕ, ÀÌ»óº¹: ½ÉÇ÷°ü°èÀÇ ÁßÃß¼º Á¶Àý±âÀü¿¡ ´ëÇÑ prostaglandin E2ÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 37(1): 13-18, 1984.
È«±âºÀ, ÀÌ»óº¹: ¹«¸¶Ãë Åä³¢¿¡¼­ Ãø³ú½Ç¿¡ Åõ¿©µÈ muscarine¼º ¾à¹°ÀÌ ½ÉÇ÷°ü°è¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 37(1): 19-25, 1984.
ÀÌ¿µÈñ: AspirinÀÌ FurosemideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 37(2): 369-378, 1984.
¼­¿µÁø, À̱ÇÇà, ±è¿Á³à, ÀÌ»óº¹, Á¶±Ôö: Åä³¢ÀÇ Ç÷Àå³» Aldosterone ³óµµ¿¡ ¹ÌÄ¡´Â Aspirine°ú FurosemideÀÇ ¿µÇâ. ´ëÇѾฮÇÐȸÁö 20(2): 1-6, 1984.
À̼®¿ë, ±è¿Á³à, ÀÌ»óº¹, Á¶±Ôö: ÈòÁãÀÇ Ãø³ú½Ç¿¡ Åõ¿©µÈ GABA À¯»ç¹°ÁúÀÇ ½ÉÇ÷°ü°è¿¡ ´ëÇÑ ¿µÇâ. Áß¾ÓÀÇÇÐ 47(1): 35-43, 1984.
ÀÌ»óº¹, ±è¿Á³à: Á¤»ó ¹× ÀÚ¿¬ ¹ß»ý¼º °íÇ÷¾Ð ÈØÁã¿¡¼­ Ç÷¾ÐÁ¶Àý¿¡ ´ëÇÑ ÁßÃß Äݸ°¼º ´º·ÐÀÇ ¿ªÈ°. Áß¾ÓÀÇÇÐ 46(1): 1-6, 1984.
Á¶±Ôö: ºÎÁ¾°ú ÀÌ´¢Á¦. ´ëÇÑÀÇÇÐÇùȸÁö 28(12): 1179-1185, 1985.
À̼®¿ë, À̱ÇÇà, ±è¿Á³à, ÀÌ»óº¹, Á¶±Ôö: ÈòÁãÀÇ ½ÅÁ¶Á÷³» Cyclic Nucleotide ÇÔ·®¿¡ ´ëÇÑ Aspirin, Indomethacin ¹× Furosemide ÀÇ »óÈ£ÀÛ¿ë. ÃÖ½ÅÀÇÇÐ 38(6): 40-46, 1985.
À̸í¿ì, ÀÌ»óº¹: ÈòÁã Ãø³ú½Ç¿¡ Åõ¿©ÇÑ muscimolÀÇ ½ÉÇ÷°ü ÀÛ¿ë ¹× ÁßÃß¼º Äݸ°½Å°æÀü´Þ°úÀÇ °ü°è. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 38(2): 501-511, 1985.
ÇÑÅ¿ø, ÀÌ»óº¹: Åä³¢ Ãø³ú½Ç¿¡ Åõ¿©ÇÑ Nicotine¼º ¾à¹°ÀÌ ½ÉÇ÷°ü°è¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 38(3): 677-684, 1985.
ÀÌ»óºÀ, ÀÌ»óº¹: Åä³¢¿¡¼­ FurosemideÀÇ ¿°¼Ò¹è¼³ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¥ãAminobutyric AcidÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 38(4): 873-881, 1985.

<1986¡­1990>
<±¹ ³»>

À̱ÇÇà, È«°æÀÚ, ½ÅÀͱÕ, ±è¿Á³à, ÀÌ»óº¹, Á¶±Ôö: Åä³¢¿¡¼­ ProcaineÀÇ Àü½ÅÅõ¿©°¡ ½Å±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. ÃÖ½ÅÀÇÇÐ 29(6): 39-44, 1986.
À̱ÇÇà, Á¶±Ôö: Ä®½·ÀÌ ÀûÃâ °ü·ù Åä³¢ ½ÅÀå¿¡¼­ FurosemideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 39(4): 1109-1118, 1986.
±èÇмú: ÈòÁã ½ÅÁ¶Á÷³» Guanylate Cyclase¿¡ ´ëÇÑ FurosemideÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 39(2): 395-403, 1986.
ÀÌÃæÈÆ, Á¶±Ôö: Furosemide°¡ ÀûÃâ °ü·ù Åä³¢½ÅÀå ±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 39(2): 529-537, 1986.
Áøµ¿Âù, ±è¿Á³à: AspirinÀÌ BenzothiadiazideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 39(3): 741-749, 1986.
À̿쿵, Á¶±Ôö: Hydrochlorothiazide°¡ ½ÅÀå±â´É ¹× ½ÅÁ¶Á÷³» Cyclic Nucleotides ÇÔ·®¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 39(4): 1099-1108, 1986.
½ÅÀͱÕ, ÀÌ»óº¹: ÈòÁã º¹¿ÜÃø ¿¬¼öÀÇ ½Â¾ÐºÎÀ§¿¡¼­ ½ÉÇ÷°ü Á¶Àý¿¡ ´ëÇÑ GABA¼º ±âÀü. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 39(4): 1119-1128, 1986.
Lee SY, Koh TL, Lee WY, Lee SB, Cho KC: Effects of hydrochlorothiazide on the renal cyclic nucleotides level. Kor J Pharmacol 22(2): 128-134, 1986.
Lee KH, Chun EE, Hong KJ, Cho KC: Role of calcium in function of isolated perfused rabbit kidney. Kor J Pharmacol 22(2): 135-143, 1986.
Kim SY, Koh TL, Lee SB: Cholinergic mechanisms on cardiovascular regulation in the ventrolateral medulla of the rat. Kor J Pharmacol 23(2): 77-85, 1987.
À̱ÇÇà, À̼®¿ë, ±è¿Á³à, ÀÌ»óº¹, Á¶±Ôö: Ä®½· ±æÇ×Á¦°¡ ÀûÃâ °ü·ù Åä³¢½ÅÀå ±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ. ÃÖ½ÅÀÇÇÐ 30(5): 63-67, 1987.
ÀüÀºÀÇ, Á¶±Ôö: QuinidineÀÌ ÀûÃâ°ü·ù Åä³¢½ÅÀå¿¡¼­ FurosemideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 40(1): 41-49, 1987.
ÀÓ¿ÏÈñ, Á¶±Ôö: DiltiazemÀÌ Åä³¢½ÅÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 40(1): 51-59, 1987.
±èÁøÇÑ, Á¶±Ôö: ÀûÃâ°ü·á Åä³¢½ÅÀå¿¡¼­ ¾Æ½ºÇǸ°ÀÌ Ä®½·ÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 40(3): 651- 658, 1987.
À±¿©È«, ÀÌ»óº¹: ÈòÁã º¹¿ÜÃø ¿¬¼öÀÇ ½Â¾ÐºÎÀ§¿¡¼­ ½ÉÇ÷°ü Á¶Àý¿¡ ´ëÇÑ Muscarine¼º ±âÀü. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 41(1): 43-52, 1988.
ÀÌ¿ë¿ì, ÀÌ»óº¹: ÈòÁã °í¼ÓÇÙ¿¡ ¹Ì¼¼ÁÖ»çÇÑ Nicotine¼º ¾à¹°ÀÇ ½ÉÇ÷°ü ÀÛ¿ë. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 41(1): 53-60, 1988.
°íÅø³, ÀÌ»óº¹: ÈòÁã °í¼ÓÇÙ¿¡¼­ ½ÉÇ÷°üÁ¶Àý¿¡ ´ëÇÑ Choline¼º ±âÀü. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 40(2): 501-511, 1988.
ÀÓ¿ë°É: ÀûÃâ°ü·ù Åä³¢½ÅÀå¿¡¼­ Ä®½·ÀÌ AmilorideÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 41(2): 711-721, 1988.
À̱ÇÇà, ¼º±â¿í, È«°æÀÚ, ÀÌ»óº¹, Á¶±Ôö: ÀûÃâ°ü·ù Åä³¢½ÅÀå±â´É¿¡ ´ëÇÑ Å°´ÑÀÇ ¿µÇâ. ´ëÇѽÅÀåÇÐȸ ÀâÁö 7(1): 18-25, 1988.
À̱ÇÇà, Á¶±Ôö: Á¤»ó ¹× ÀÌ´¢¼º ÈòÁã ½ÅÀå Á¶Á÷¿¡¼­ »ïÅõ¼º À¯±â¹°ÁúÀÇ ³óµµ. ´ëÇѽÅÀåÇÐȸ 8(3): 407-414, 1989.
ÀÓºÀ¿­, Á¶±Ôö: ÀûÃâ°ü·ù Åä³¢½ÅÀå¿¡¼­ Ä®½·ÀÌ BradykininÀÇ ÀÌ´¢ÀÛ¿ë¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐÀÇÇкΠ³í¹®Áý 42: 41-49, 1989.
Ȳ±âÇö, Á¶±Ôö: Á¤»ó ¹× ÀÌ´¢¼º Åä³¢½ÅÀå¿¡¼­ ¾Æ¹Ì³ë»êÀÇ ³óµµ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 42(4): 901-909, 1989.
¹Ú¼öÇå, ±è¿Á³à: ÈòÁ㠽ż¼´¢°üÀÇ »ê¼Ò¼Òºñ·®¿¡ ´ëÇÑ BradykininÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 43(1): 145-152, 1989.
¼º±â¿í, ±è¼ºÀ±, ÀÌ»óº¹, Á¶±Ôö: ÈòÁã °í¼ÓÇÙ¿¡¼­ ½ÉÇ÷°ü Á¶Àý¿¡ ´ëÇÑ Serotonin¼º ±âÀü. ´ëÇÑÀÇÇÐÇùȸÁö 32(7): 743-750, 1989.
±è´ë¿ì, ÀÌ»óº¹: ¸¶ÃëÇÑ Á¤»óÇ÷¾Ð ¹× ÀÚ¿¬¹ß»ý¼º °íÇ÷¾Ð ÈòÁãÀÇ °í¼ÓÇÙ¿¡ Á¸ÀçÇÏ´Â Choline¼º ¼ö¿ëü¿¡ ÀÇÇÑ ½ÉÇ÷°ü±â´ÉÀÇ Á¶ÀýÀÛ¿ë. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 42(1): 527-538, 1989.
Lee SY, Ro KS, Kim ON, Lee SB, Cho KC: Effects of loop diuretics on guanylate cyclase in rat medullary thick ascending limb of Henle's loop. Kor J Pharmacol 25(1): 59-66. 1989.
¼º±â¿í, ÀÌ»óº¹: Á¤»óÇ÷¾Ð¹× ÀÚ¿¬ ¹ß»ý¼º °íÇ÷¾Ð ÈòÁãÀÇ º¹¿ÜÃø ¿¬¼ö¿¡ Á¸ÀçÇÏ´Â choline¼º ¼ö¿ëü¿¡ ÀÇÇÑ ½ÉÇ÷°ü Á¶Àý±â´É. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 43(1): 35-45, 1990.
Áøµ¿Âù, ±è¿Á³à: BradykininÀÌ ¹è¾çµÈ ½ÅÇÇÁú ¼¼´¢°ü ¼¼Æ÷³» Ä®½·³óµµ¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 43(4): 1111-1118, 1990.
¹Ú¼öÇå, ±è¿Á³à: ÈòÁ㠽ż¼´¢°üÀÇ »ê¼Ò ¼Òºñ·®¿¡ ´ëÇÑ BradykininÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 43(2): 47-53, 1990.
¼ÛÀΰü: ÈòÁã ½ÅÀåÇÇÁú ¼¼´¢°üÀÇ »ê¼Ò¼Òºñ·®¿¡ ´ëÇÑ BradykininÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 43(2): 669-677, 1990.
Lee SY, Cho KC: Effect of bradykinin on oxygen consumption in the distal tubule and cortical collecting tubule of rat. Kor J Pharmacol 26(2): 161-166, 1990.
<±¹ ¿Ü>
Lee SB, Sung KW, Kim SY, Cho KC: Cholinergic mechanisms on cardiovascular regulation in the nucleus tractus solitarius: funtional relationship between cholinergic neuron & L-glutamate. Eur J Pharmacol 183(5): 1927, 1990.

<1991¡­1995>
<±¹ ³»>

±èº¸¿¬, ÀÌ»óº¹: ÀÔ¿øÁßÀÎ Á¤½ÅÁõ ȯÀÚ¿¡¼­ ¾à¹° ºñ¼øÀÀÀÇ °ü·Ã¿äÀÎ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 44(1): 45-55, 1991.
±è¼ºÀ±, Á¶¿µÁø, ¼º±â¿í, ±èÁ¤È¸, ±è¿Á³à, ÀÌ»óº¹: °í¼Ó¾×ü Å©·Î¸¶Åä±×¶óÇǸ¦ ÀÌ¿ëÇÑ Ciprofloxacin µÎ Á¦Á¦ÀÇ »ý¹°ÇÐÀû µ¿µî¼ºÀÇ ½ÃÇè. °¨¿° 23(4): 271-278, 1991
±è±Ô¾ð, ±è¿Á³à: ÈØÁã ½ÅÀå³»¼öÁúÁýÇÕ°ü »óÇǼ¼Æ÷ÀÇ »ê¼Ò¼Òºñ·®¿¡ ´ëÇÑ BradykininÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 44(2): 379-389, 1991.
³ë°æ½Ä, ÀÌ»óº¹: ÈòÁã ½ÅÀå ±ÙÀ§¼¼´¢°üÀÇ Na-K-ATPaseÈ°¼º°ú »ê¼Ò ¼Òºñ·®¿¡ ´ëÇÑ ClonidineÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 44(4): 1001-1010, 1991.
¹ÚÀοø, ÀÌ»óº¹: ÈØÁã ¸Á¸·¿¡¼­ GABA“G Dopamine¼º ½Å°æ¿øÀÇ ºÐÆ÷¿Í ÀÌµé ¼¼Æ÷¿¡¼­ÀÇ GABA¹× DopamineÀÇ °øÁ¸. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 45(1): 43-50, 1992.
Sung KW, Kim SY, Cho YJ, Lee KH, Lee SB: In vivo measurement of extracellular monoamines and their meta- bolites in the rat posterior hypothalamus using microdialysis technique. Kor J Pharmacol 28(1): 1-8, 1992.
¼­º¸¿ø: ÈòÁ㠽ſø ºÐÀý¿¡¼­ ATP ¾ç¿¡ ´ëÇÑ ¾Æ¹Ì³ë±Û¶óÀ̵å Ç×»ýÁ¦ÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 45(2): 1-11, 1992..
ÃÖµ¿È£, ÀÌ»óº¹: ÈòÁã½ÅÀå¿¡¼­ Cisplatin¿¡ ÀÇÇÑ ÁöÁú°ú»êÈ­¿¡ ´ëÇÑ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý, 1992.
À̼®¿ë, ÀÌ»óº¹: ÈòÁã³» ¼öÁúÁýÇÕ°ü ¼¼Æ÷ÀÇ ´Éµ¿Àû Sodium¿î¹Ý¿¡ ´ëÇÑ Bradykinin°ú IndomethacinÀÇ ¿µÇâ. ÃÖ½ÅÀÇÇÐ 35, 54-60, 1992.
À̼®¿ë, Á¶±Ôö: ÈòÁã³» ¼öÁúÁýÇÕ°ü ¼¼Æ÷¿¡¼­ cGMP»ý¼º¿¡ ´ëÇÑ ANP¿Í AmilorideÀÇ »óÈ£ÀÛ¿ë. ÃÖ½ÅÀÇÇÐ 35, 11-16, 1992.
±è¼ºÀ±, ÀÌ»óº¹: Á¤»óÇ÷¾Ð ¹× ÀÚ¿¬¹ß»ý¼º °íÇ÷¾Ð ÈòÁã¿¡¼­ Ç÷¾Ð°ú Ç÷Àå Ä«Å×ÄݾƹΠ³óµµ¿¡ ´ëÇÑ Äݸ°¿¡½ºÅͶóÁ¦ ¾ïÁ¦¾àÀÇ ÁßÃßÀÛ¿ë. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý. 46(4): 1265-1276, 1993.
±èÀμø, À̼®¿ë, ±èÁ¤È¸, Á¶¿µÁø, ÀÌ»óº¹: Ç÷°ü»ý¼º ¹× °ü»ó±¸Á¶ Çü¼º¿¡ ¹ÌÄ¡´Â È÷½ºÅ¸¹ÎÀÇ ¿µÇâ. ´ëÇѾÏÇÐȸÁö 25, 607-615, 1993
Kim IS, Lee SB, Cho KC: Phosphorylation of ribosomal protein S6 and its regulation during differentiation of human leukemic cells. J Kor Med Sci 8: 413-419, 1993.
ÃÖµ¿È£, ÀÌ»óº¹: ÈòÁã ½ÅÀå¿¡¼­ ÁöÁú°ú »êÈ­¿¡ ´ëÇÑ CisplatinÀÇ ¿µÇâ, °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý. 46(1): 21-29, 1993.
Á¶¿µÁø, Á¶±Ôö: Effects of cisplatin on free radical scavenging enzymes and inhibitors of cisplatin-induced nephroxicty by free radical scavengers. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 46(3): 753-762, 1993.
ÀÓºÀ¿­, ÀÌ»óº¹: Cisplatin Åõ¿©°¡ ÈòÁã ½ÅÀåÀÇ È°¼º»ê¼Ò Á¦°ÅÈ¿¼Ò È°¼º¿¡ ¹ÌÄ¡´Â ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 46(4): 1255-1263, 1993.
±è¼ºÀ±, ¼º±â¿í, ±èÁ¤Áø, Á¶¿µÁø, ±è¿Á³à, ÀÌ»óº¹: °æ±¸Åõ¿©ÇÑ ofloxacine Á¤Á¦ÀÇ »ýü ÀÌ¿ëÀ²ÀÇ ºñ±³. ÀÓ»ó¾à¸®ÇÐȸÁö. 2(1): 21-29, 1994.
¹ÚÀοø: ÈòÁã ¸Á¸·¿¡¼­ Substance P¼º ½Å°æ¿øÀÇ ÀÎÁ¢±â±¸¿¡ ´ëÇÑ ¸é¿ª¼¼Æ÷È­ÇÐÀû ¿¬±¸. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 47(4): 1417-1430, 1994.
°íÇöö: ÁßÃß Ç÷¾Ð Á¶Àý¿¡ À־ ô¼ö Nitric OxideÀÇ ¿ªÇÒ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 47(4): 1431-1442, 1994.
¿À¼¼±â, ÀÌ»óº¹: ÈòÁã ³»¼öÁú ÁýÇÕ°ü ¼¼Æ÷¿¡¼­ Atrial Natriuretic PeptideÀÇ ¼ö¿ëü °áÇÕ°ú ÀüÇØÁú ¿î¹Ý ¾ïÁ¦ÀÛ¿ë¿¡ ´ëÇÑ AmilorideÀÇ ¿µÇâ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 47(1): 97-105, 1994.
¾çµ¿¿ø, ÀÌ»óº¹: N-Methyl-D-Asparate ¼ö¿ëü ±æÇ×ü MK-801ÀÇ ÈòÁã ½ÉÇ÷°ü°è¿¡ ´ëÇÑ ÀÛ¿ë. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý 48(1): 21-32, 1995.
Kim SH, Cho YJ, Bae YJ, Lee KH, Lee SB: Effect of biphenyl bicarboxylate on chemical-induced hepatotoxicity. Kor J Toxicol 11(2): 181-185, 1995.
ÃÖµ¿È£, ÀÌ»óº¹: L6±ÙÀ°¼¼Æ÷ÀÇ ºÐÈ­½Ã phospholipase C µ¿À§È¿¼ÒÀÇ ºÐÆ÷ÇüÅÂ. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý. 48(4): 965-977, 1995.
¼º±â¿í¿Ü 9ÀÎ: Á¤»ó¼ºÀο¡ °æ±¸Åõ¿©ÇÑ Levofloxacin µÎÁ¤Á¦ÀÇ »ýü ÀÌ¿ëÀ²ÀÇ ºñ±³. ÀÓ»ó¾à¸®ÇÐȸÁö 3(2): 169-176, 1995.
±è°æ¼ö: ÈòÁã Ç÷¾× ¹× ³ú Á¶Á÷º° haloperidolÀÇ ºÐÆ÷¿¡ ´ëÇÑ ¾àµ¿ÇÐÀû »ó°ü¼º. °¡Å縯´ëÇÐ ÀÇÇкΠ³í¹®Áý. 49(2): 1-11, 1995.

<±¹ ¿Ü>
Lee SB, Kim SY, Sung KW: Cardiovascular regulation by cholinergic mechanisms in rostral ventrolateral medulla of spontaneously hypertensive rats. Eur J Pharmacol 205: 117-123, 1991.
Beits JG, Kim IS, Calabresi P, Frackeltan AR Jr: Human microvascular endothelial cells express receptors for platelet-derived growth facter. Proc Natl Acad Sci 88: 2021-2025, 1991.
Endou H, Jung KH, Lee KH: Role of ammonium ion in adenine triphosphate consumption of the rat medullary thick ascending limb. Contribution to Nephrology 92: 149-159, 1991.
Lee KH, Lee SB, Cho KC: Levels of organic osmolytes in normal and diuretic rat kidney. Contributions to Nephrology 95: 279-283, 1991.
Kim SY, Sung KW, Kim YJ, Lee SY, Lee SB: Cardiovascular effects of various cholinergic agents in nucleus tractus solitarius: Role of muscarinic and nicotinic receptors. Asia Pacific J Pharmacol 7: 183-190, 1992.
Beitz JB, Kim I-S, Calabresi P, Frackelton AR Jr: Receptors for platelet-derived growth factor on microvascular endothelial cells. In Angiogenesis: Key Principles Science Technology-Medicine. ed. by Steiner R, Weisz PB, Langer R. pp 85-90. Birkh user Verlag, Basel, 1993.
Diefer-Day JS, El-Sayed AMA, Forray C, Lee NH, Kim ON, El-Fakahany EE: Effects of tacrine on brain muscarinic-receptor-mediated second-messenger signals. Pharmacol 47: 98-110, 1993.
Jhon D-Y, Lee H-H, Park D, Lee C-W, Lee K-H, Yoo OJ, Rhee SG: Cloning, sequencing, purification, and Gq-dependent activation of phospholipase C-¥â3. J Biol Chem 268(9): 6654-6661, 1993.
Park D, Jhon D-Y, Lee C-W, Lee K-H, Rhee SG: Activation of phospholipase C isozymes by G protein ¥â¥ã subunits. J Biol Chem 268(7): 4573-4576, 1993.
Lee CW, Lee KH, Lee SB, Park D, Rhee SG: Regulation of phospholipase C-¥â4 by ribonucleotides and the ¥á subunit of Gq. J. Biol. Chem. 269: 25335-25338, 1993..
Lee CW, Park DJ, Lee KH, Kim CK, Rhee SG: Purification molecular cloning, sequencing of phospholipase C-¥â4. J Biol Chem 268, 21318-21327, 1993.
Lee CW, Lee KH, Rhee SG: Purification of phospholipase C-¥â4 and phospholipase C-¥ä2 from bovine retinas. Methods in Neurosciences 18; 64-71, 1993.
Lee CW, Lee KH, Kim CK, Rhee SG: Characterization of PLC isozymes in bovine retina: Purification of phospholipase C-¥â4. Methods in Enzymology 238; 227-237, 1994.
Lee KH, Cho YJ, Lee SB, Cho KC, Cha SH, Endou H: Evidence suggesting a role for phospholipase C isozyme, PLC-¥ä1 in corticomedullary osmotic gradients in rat kidneys. Biochem Mol Biol Internat 37: 25-32, 1995.
Lee SY, Kim ON, El-Fakahany EE: Inhibition of neuronal nitric oxide synthase by antidepressants. Pharma Comm 7: 1-9, 1995.
Zhu SZ, Lee SY, Wang SZ, El-Fakahany EE: Investigation of the role of an amino acid triplet repeat in differentiation drug-receptor interaction at m1 and m2 muscarinic receptors. Pharmacology. 51: 298-307, 1995

<1996¡­>
<±¹ ³»>

Lee SY, Lee SB: Effects of site-mutagenesis of an amino acid triplet repeat at M1 and M2 muscarinic receptors on receptor function. Kor J Pharmacol 32:311-321, 1996
Lee SY, Sung KW, Kim ON, Lee SG: Enahnced coupling of M1 muscarinic receptors to activation of phospholipase C upon mutation of a transposed amino acied triplet repeat. Kor J Physiol Pharmacol 1: 19-25, 1997.

<±¹ ¿Ü>
Lee SB, Koh HC, Kim ON, Sung KW, Kim SY: Intrathecal administration of sodium nitroprusside, a nitric oxide donor, increase blood pressure in anesthetized rats. Neuroscience Letters 203: 53-56, 1996.
Wang SZ, Lee SY, Zhu SZ, El-Fakahany EE: Dofferential coupling of m1, m3, and m5 muscarinic receptors to activation of neuronal nitric oxide synthase. Pharmacol 53: 271-280, 1996.
Lee SY, Zhu SZ, El-Fakahany EE: Role of two highly conserved tyrosine residues in the m1 muscarinic receptor second transmembrane domain in ligand binding and receptor function. Receptors Signal Transduct (formerly Receptor) 6: 43-52, 1996.

 
4. ±³À°È°µ¿

1) Çкα³À°
ÀÇÇаú 2Çгâ
1Çбâ
   °­ÀÇ 6½Ã°£/ÁÖ ½Ç½À 4½Ã°£/ÁÖ ÇÐÁ¡ 6ÇÐÁ¡
2Çбâ
   2½Ã°£/ÁÖ 0 ÇÐÁ¡ 2ÇÐÁ¡
±³  Àç
   ÁÖ±³Àç: Basic & Clinical Pharmacology
   ºÎ±³Àç: Goodman & Gilman's The Pharmacological Basis of Therapeutics
   ½Ç½À±³Àç: ¾à¸®ÇнǽÀ(´ëÇѾฮÇÐȸ Æí)

°£È£Çаú 2Çгâ
1Çбâ
   °­ÀÇ 1½Ã°£/ÁÖ ½Ç½À 3½Ã°£/ÁÖ ÇÐÁ¡ 2ÇÐÁ¡
2Çбâ
   °­ÀÇ 2½Ã°£/ÁÖ - ÇÐÁ¡ 2ÇÐÁ¡
±³  Àç
   ±âº»¾à¸®ÇÐ (Á¶±Ôö, ÀÌ»óº¹ Àú)

2) ´ëÇпø ±³À°
Çʼö°ú¸ñ
°úÁ¤
°ú¸ñ¸í
ÇÐÁ¡
±³      Àç
¼® »ç
ÀϹݾฮÇÐ
3
  Goodman & Gilman: The Pharmacological Basis of Therapeutics
¼® »ç
Áßµ¶ÇÐ
3
  Hayes AW: Principles and Methods of Toxicology
¼® »ç
Ãʵ¶
1
¹Ú »ç
¾à¿ªÇÐ
3
  Pratt WB & Taylor P: Principles of Drug Action
¹Ú »ç
¾à¹°´ë»çÇÐ
3
  Rowland M & Tocer TN: Clinical Pharmacokinetics
¹Ú »ç
ºÐÀھฮÇÐ
3
  Alberts B et al: Molecular Biology of the Cell
¹Ú »ç
Ãʵ¶
1

¼±Åðú¸ñ(¼®¡¤¹Ú»ç °øÅë)
°ú¸ñ¸í
ÇÐÁ¡
±³      Àç
Á¤½Å½Å°æ¾à¸®ÇÐ
2
  Meltzer HY: Psychopharmacology
ÀÓ»ó¾à¸®ÇÐ
2
  Rowland M: Clinical Pharmacokinetics
½ÅÀå¾à¸®ÇÐ
2
  Brenner & Rector: The Kidney

°úÁ¤º° ÃÖ¼Ò À̼öÇÐÁ¡Ç¥
¼®»ç°úÁ¤(24ÇÐÁ¡)
  Àü°ø(15ÇÐÁ¡): Ãʵ¶ 2ÇÐÁ¡, Çʼö(2°ú¸ñ) 6; ¼±ÅÃ(2°ú¸ñ) 4; Ư¼ö¿¬±¸°úÁ¦ 3
  ºÎÀü°ø(9ÇÐÁ¡): ÇÕµ¿°­ÀÇ 2ÇÐÁ¡; Çмú°­¿¬È¸ 1, ºÎÀü°ø(2-3°ú¸ñ) 6
¹Ú»ç°úÁ¤(36ÇÐÁ¡)
  Àü°ø(24ÇÐÁ¡): Ãʵ¶ 3ÇÐÁ¡, Çʼö(3°ú¸ñ) 9; ¼±ÅÃ(3°ú¸ñ) 6, Ư¼ö¿¬±¸°úÁ¦ 6
  ºÎÀü°ø(12ÇÐÁ¡): ÇÕµ¿°­ÀÇ(2°ú¸ñ) 4ÇÐÁ¡, Çмú°­¿¬È¸(2°ú¸ñ) 2, ºÎÀü°ø(2-3°ú¸ñ) 6